Fig. 2.

Differential effects of Cdk5 inhibitors were observed on steady-state [³H]WIN35,428 binding to DATs in rat dSTR membranes. A, ability of increasing concentrations of roscovitine, olomoucine, iso-olomoucine, and GW8510 to compete with 4 nM [³H]WIN35,428 binding is shown. Nonspecific binding is shown in the presence of the DAT inhibitor benztropine (2.4 μM). B, concomitant exposure to roscovitine (30 μM) did not alter the ability of AMPH to compete with 4 nM [³H]WIN35,428 binding in dSTR membranes. Data represent mean values ± S.E.M. for n = 3 to 4 independent experiments, each performed in triplicate. Dashed line represents vehicle (0.1% DMSO) control.